Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial
Authors
Keywords
BNT162b2, COVID-19, Efficacy, Malignancy, Safety, Vaccine
Journal
VACCINE
Volume 40, Issue 10, Pages 1483-1492
Publisher
Elsevier BV
Online
2021-12-24
DOI
10.1016/j.vaccine.2021.12.046
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
- (2021) Denis Y Logunov et al. LANCET
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
- (2021) Noa Dagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients
- (2021) R. Palich et al. ANNALS OF ONCOLOGY
- Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors
- (2021) J. Barrière et al. ANNALS OF ONCOLOGY
- Prostate cancer management in the era of COVID‐19: Recommendations from the Hong Kong Urological Association and Hong Kong Society of Uro‐oncology
- (2021) Darren Ming‐Chun Poon et al. Asia-Pacific Journal of Clinical Oncology
- Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia
- (2021) Yair Herishanu et al. BLOOD
- Low Neutralizing Antibody Responses Against SARS-CoV-2 in Elderly Myeloma Patients After the First BNT162b2 Vaccine Dose
- (2021) Evangelos Terpos et al. BLOOD
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
- (2021) Brian J. Boyarsky et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors
- (2021) Barliz Waissengrin et al. LANCET ONCOLOGY
- Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
- (2021) Leticia Monin et al. LANCET ONCOLOGY
- Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
- (2021) Laith J. Abu-Raddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma
- (2021) Sarah Bird et al. Lancet Haematology
- Safety and Immunogenicity of Anti–SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants
- (2021) Olivier Marion et al. ANNALS OF INTERNAL MEDICINE
- Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
- (2021) P. Grivas et al. ANNALS OF ONCOLOGY
- Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients
- (2021) P. Heudel et al. ANNALS OF ONCOLOGY
- Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer
- (2021) Alfredo Addeo et al. CANCER CELL
- Seroconversion rates following COVID-19 vaccination among patients with cancer
- (2021) Astha Thakkar et al. CANCER CELL
- Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
- (2021) Lee M. Greenberger et al. CANCER CELL
- COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
- (2021) Yu-Wei Chen et al. EUROPEAN JOURNAL OF CANCER
- Safety and efficacy of BNT162b mRNA Covid19 Vaccine in patients with chronic lymphocytic leukemia
- (2021) Ohad Benjamini et al. HAEMATOLOGICA
- Real-world patient-reported and clinical outcomes of BNT162b2 mRNA COVID-19 vaccine in patients with cancer.
- (2021) Ishwaria Mohan Subbiah et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes of COVID-19 in Patients With Cancer: Report From the National COVID Cohort Collaborative (N3C)
- (2021) Noha Sharafeldin et al. JOURNAL OF CLINICAL ONCOLOGY
- Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors
- (2021) Evangelos Terpos et al. Journal of Hematology & Oncology
- Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
- (2021) Robert W. Frenck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients
- (2021) Nassim Kamar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
- (2021) Stephen J. Thomas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma
- (2021) Sean H Lim et al. Lancet Haematology
- Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
- (2021) Amir Massarweh et al. JAMA Oncology
- Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment
- (2021) Noa Eliakim-Raz et al. JAMA Oncology
- Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer
- (2021) Tal Goshen-Lago et al. JAMA Oncology
- COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience
- (2021) Alfred Chung Pui So et al. Cancers
- High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers
- (2021) R. Palich et al. ANNALS OF ONCOLOGY
- Survival study of hospitalised patients with concurrent COVID‐19 and haematological malignancies
- (2020) Fernando Martín‐Moro et al. BRITISH JOURNAL OF HAEMATOLOGY
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
- (2020) Nicole M Kuderer et al. LANCET
- Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers
- (2020) Jia Luo et al. Cancer Discovery
- Managing cancer patients during the COVID-19 pandemic: An ESMO Interdisciplinary Expert Consensus
- (2020) G. Curigliano et al. ANNALS OF ONCOLOGY
- Determinants of COVID-19 disease severity in patients with cancer
- (2020) Elizabeth V. Robilotti et al. NATURE MEDICINE
- COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
- (2020) Lennard Y W Lee et al. LANCET ONCOLOGY
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started